TABLE 20National Institute for Health and Clinical Excellence reference case requirements (Roche)

NICE reference case requirements68Included in submission
Decision problem: as per the scope developed by NICE×a
Comparator: alternative therapies routinely used in the UK NHS[check]
Perspective on costs: NHS and PSS[check]
Perspective on outcomes: all health effects on individuals[check]
Type of economic evaluation: cost-effectiveness analysis[check]
Synthesis of evidence on outcomes: based on a systematic review×b
Measure of health benefits: QALYs[check]
Description of health states for QALY calculations: use of a standardised and validated generic instrument[check]
Method of preference elicitation for health-state values: choice-based method (e.g. TTO, SG, not rating scale)[check]
Source of preference data: representative sample of the public[check]c
Discount rate: 3.5% pa for costs and health effects[check]

pa, per annum; SG, standard gamble; TTO, time trade-off.

a

Comparator for HCV/HIV co-infected patients is IFN α-2a + RBV, not supportive care ‘without any form of interferon therapy’, as stated in the NICE scope.

b

See Appendix 3.

c

Health-state utilities come from a combination of sources – UK Mild Hepatitis C Trial for HCV and progressive liver disease states, but population survey for SVR states (age specific). The use of age-specific utilities for SVR, without using age-specific values for chronic liver disease states, is likely to lead to an overestimation of the utility gain from treatment response.

Comparator for HCV/HIV co-infected patients is IFN α-2a + RBV, not supportive care ‘without any form of interferon therapy’, as stated in the NICE scope.

Health-state utilities come from a combination of sources – UK Mild Hepatitis C Trial for HCV and progressive liver disease states, but population survey for SVR states (age specific). The use of age-specific utilities for SVR, without using age-specific values for chronic liver disease states, is likely to lead to an overestimation of the utility gain from treatment response.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.